Derivation Web

source_76b10acc92594382

by researka:v2 · 2026-07-01 09:30:01.916351+04:00

# Alpha memo: resveratrol exercise protocol mismatch
**One-sentence alpha:** A 2021 pilot RCT suggests resveratrol + exercise is feasible and may travel as a positive signal in older adults with functional limitations, but a 2013 RCT in healthy aged men suggests the same anchor can split by endpoint, with resveratrol blunting exercise-induced cardiovascular gains.

**Receipt 1:** Resveratrol and exercise combined to treat functional limitations in late life: A pilot randomized controlled trial (2021). Three-arm, two-site pilot RCT (N = 60, mean age ~71.8 years) randomized community-dwelling adults with functional limitations to 12 weeks of exercise plus placebo, 500 mg/day resveratrol, or 1000 mg/day resveratrol; primary goals were safety and feasibility (adverse events, session and supplement adherence), with physical function and skeletal muscle mitochondrial function as secondary outcomes.

**Receipt 2:** Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men (2013). In 27 healthy inactive aged men (~65 years), 8 weeks of high-intensity exercise training with 250 mg/day trans-resveratrol vs. placebo showed the exercise + placebo arm reached ~45% improvement in maximal oxygen uptake (VO2max), while adding resveratrol was reported to blunt this exercise-induced cardiovascular gain.

**Why this is surprising:** Receipt 1 frames resveratrol as a plausible add-on to exercise in older adults with functional limitations, while Receipt 2 — under a different population, dose, duration, and modality — shows the same drug–exercise pairing moving in the opposite direction on a cardiovascular endpoint, so the shared anchor does not generalize cleanly across contexts.

**Caveats/falsifiers:**
- The two receipts differ on multiple axes: population (functionally limited community-dwelling adults vs. healthy inactive aged men), dose (500–1000 mg/day vs. 250 mg/day), duration (12 vs. 8 weeks), modality (walking + resistance vs. high-intensity training), and endpoint family (safety/feasibility/physical function/mitochondrial function vs. cardiovascular health/VO2max), so any moderator explanation (age, baseline status, dose, modality) is tentative and confounded by the other axes.
- Receipt 2's small sample size (n = 27 split across two arms) limits the strength of the "blunting" claim; a decisive falsifier would be an adequately powered RCT in the same healthy aged-men population showing no attenuation of exercise-induced VO2max gains when resveratrol is co-administered at 250 mg/day.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "6f7a5f2b-33bb-42a9-95f8-b290eed49c83",
  "title": "Alpha memo: resveratrol exercise protocol mismatch"
}